Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Insulet Corporation    PODD

INSULET CORPORATION

(PODD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Insulet : Issues Medical Device Correction Regarding its Omnipod DASH™ Insulin Management System

share with twitter share with LinkedIn share with facebook
share via e-mail
02/13/2020 | 06:03am EST

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced a voluntary Medical Device Correction for all Omnipod DASH™ Personal Diabetes Managers (PDMs) distributed globally.

Consumer safety is Insulet’s top priority and this action is taken voluntarily with the knowledge of the FDA.

As part of our ongoing quality monitoring processes, we have identified that on rare occasions, the Omnipod DASH PDM may suggest an inaccurate bolus amount based on a blood glucose value that is more than 10 minutes old when the user does not exit the bolus calculator as designed or when a system alarm interrupts a bolus calculation. If the user delivers the bolus, this may result in over or under delivery of insulin which may lead to hypoglycemia or hyperglycemia. No injuries have been reported as a result of this potential issue and the Omnipod DASH System is safe for continued use and distribution.

This notice does not affect the Omnipod DASH Pods or the widely distributed Omnipod Insulin Management System. All affected Omnipod DASH users are being notified by email and local mail and replacement devices will be made available starting in March to all Omnipod DASH users. Additional information can be found on our website www.omnipod.com.

For further questions regarding the information provided in this Medical Device Correction, consumers are requested to contact Insulet’s 24/7 Customer Care in any of the following markets:

US: 1-800-581-6359

United Kingdom: 0800 011 6132

Netherlands: 0800 0229512

Italy: 800 798 659

About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.omnipod.com.

© 2020 Insulet Corporation. Omnipod and DASH are trademarks or registered trademarks of Insulet Corporation. All rights reserved.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on INSULET CORPORATION
02/24INSULET : to Present at Upcoming Investor Conferences
BU
02/20INSULET CORPORATION : annual earnings release
02/19INSULET : Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexc..
BU
02/19ABBOTT : and Insulet Partner to Integrate Next-Generation Glucose Sensing and Au..
PR
02/13INSULET : Issues Medical Device Correction Regarding its Omnipod DASH™ Ins..
BU
01/06INSULET : to Announce Fourth Quarter and Full Year 2019 Financial Results on Feb..
BU
2019INSULET : to Present at 38th Annual J.P. Morgan Healthcare Conference
BU
2019INSULET : First Patients in Europe Start Using Insulet's New Omnipod DASH™..
BU
2019INSULET : to Present at Upcoming Investor Conferences
BU
2019INSULET : Management's Discussion and Analysis of Financial Condition and Result..
AQ
More news
Financials (USD)
Sales 2019 727 M
EBIT 2019 49,3 M
Net income 2019 13,4 M
Debt 2019 538 M
Yield 2019 -
P/E ratio 2019 959x
P/E ratio 2020 281x
EV / Sales2019 18,4x
EV / Sales2020 15,2x
Capitalization 12 816 M
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 185,67  $
Last Close Price 207,31  $
Spread / Highest target 19,6%
Spread / Average Target -10,4%
Spread / Lowest Target -39,7%
EPS Revisions
Managers
NameTitle
Shacey Petrovic President, Chief Executive Director & Director
Timothy J. Scannell Independent Chairman
Charles Alpuche Chief Operations Officer & Executive VP
Wayde Dwight McMillan Chief Financial Officer
Aiman Abdel-Malek Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INSULET CORPORATION21.09%12 816
MEDTRONIC PLC-0.15%149 297
ABBOTT LABORATORIES0.68%149 239
STRYKER CORPORATION2.67%80 740
BECTON, DICKINSON AND COMPANY-7.88%67 937
BAXTER INTERNATIONAL INC.7.07%45 710